Communiqués Novartis AG

Actions

NOVN

CH0012005267

Produits pharmaceutiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:05 18/06/2025			Varia. 5j.	Varia. 1 janv.
94,97 ^CHF	-0,63 %		-2,66 %	+7,07 %

18/06	R&D: les plus grandes sociétés ralentissent leurs investissements	AW
18/06	Bourse Zurich: attentisme avant la Fed	AW

Communiqués

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH	12/06	GL
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer	02/06	GL
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis	01/06	GL
Novartis announces commencement of tender offer to acquire Regulus Therapeutics	27/05	GL
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline	15/05	GL
Novartis : Earnings Document (novartis q1 2025 impact and sustainability update)	05/05	PU
New $1.7b Novartis acquisition to advance novel microRNA inhibitor	01/05	AQ
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure	30/04	GL
Novartis: Q1 Earnings Snapshot	29/04	AQ
Novartis : Earnings Document (novartis target patient populations 2025)	29/04	PU
Novartis : Earnings Document (2025 04 interim financial report en)	29/04	PU
Novartis : Earnings Document (q1 2025 investor presentation)	29/04	PU
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1	29/04	GL
Barbara Weber, M.D., Elected to ITM Supervisory Board	10/04	AQ
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)	03/04	GL
CD Milan, March 27, 2025, Procedural Order On Application To Intervene, UPC_CFI_698/2024	02/04	AQ
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis	31/03	GL
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer	28/03	GL
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis	25/03	GL
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)	21/03	GL
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA	19/03	GL
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting	10/03	AQ
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting	07/03	GL
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)	28/02	GL
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)	28/02	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

NOVARTIS : résultats du premier trimestre supérieurs aux attentes ; perspectives revues à la hausse

Le 29 avril 2025 à 13:58

Le PDG de Novartis déclare qu'il faudra "s'attaquer à la rhétorique" dans le secteur de la santé aux États-Unis

Le 21 janvier 2025 à 21:33

Novartis AG : Résultats en trompe-l'oeil

Le 01 février 2024 à 11:42